F
FibroBiologics, Inc. (FBLG)
NCM – Real Time Price. Currency in USD
1.11
+0.08 (7.77%)
At close: Aug 12, 2026, 4:00 PM EDT
1.10
-0.01 (-0.73%)
After-hours: Aug 12, 2026, 5:54 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.11
+0.08 (7.77%)
At close: Aug 12, 2026, 4:00 PM EDT
1.10
-0.01 (-0.73%)
After-hours: Aug 12, 2026, 5:54 PM EDT
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Name | Position |
|---|---|
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Mr. Jason D. Davis CPA | Chief Financial Officer |
| Mr. Peter O'Heeron | Founder, Chairperson & CEO |
| Mr. Ruben A. Garcia J.D. | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-07-31 | DEF 14A | fblg-20260731.htm |
| 2026-07-31 | 10-Q | fblg-20260630.htm |
| 2026-07-24 | 8-K | fblg-20260722.htm |
| 2026-07-17 | PRE 14A | fblg-20260717.htm |
| 2026-07-10 | S-3 | fblg-20260709.htm |
| 2026-07-09 | 8-K | fblg-20260702.htm |
| 2026-06-29 | D | |
| 2026-06-23 | 8-K | fblg-20260622.htm |
| 2026-05-06 | 8-K | fblg-20260505.htm |
| 2026-05-05 | DEFA14A | fblg-20260504.htm |